CytomX Therapeutics Inc (NAS:CTMX)
$ 1.2 0 (0%) Market Cap: 93.74 Mil Enterprise Value: -31.70 Mil PE Ratio: 8.57 PB Ratio: 0 GF Score: 55/100

Q3 2019 CytomX Therapeutics Inc Earnings Call Transcript

Nov 07, 2019 / 10:00PM GMT
Release Date Price: $6.15 (+0.82%)
Operator

Good day, ladies and gentlemen, and welcome to the CytomX Therapeutics Third Quarter 2019 Financial Results Conference Call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Christopher Keenan, Vice President of Investor Relations. Chris, you may begin.

Christopher S. Keenan
CytomX Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, Sia. Good afternoon, and thank you for joining us. Earlier today, we issued a press release that includes a summary of our recent progress and third quarter 2019 financial results. This press release and a recording of this call can be found under the Investors and News section of our website at cytomx.com.

With me today are CytomXâ President, Chief Executive Officer and Chairman, Dr. Sean McCarthy, CytomXâ newly appointed Chief Development Officer, Dr. Amy Peterson; and CytomXâ Vice President of Finance, Robin Knifsend.

During today's call, we will be making forward-looking statements. Because forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot